Key Highlights

  • Third-quarter 2026 Revenue was USD 6.0 million, against USD 6.9 million a year earlier.
  • Gross Margin improved to 55% from 39.1% in the prior-year quarter.
  • The company shipped 26 systems, including eight carried over from the second quarter.
  • Cash, restricted cash and equivalents were USD 12.9 million at September 30, 2026.

Sensus Healthcare (NASDAQ:SRTS) reported third-quarter 2026 revenue of USD 6.0 million, against an estimate of USD 6.61 million. Net loss per share was USD 0.09, against an estimate of a loss of USD 0.06. The Boca Raton, Florida-based medical device company provides non-invasive treatments for oncological and non-oncological skin conditions.

Chairman and Chief Executive Officer Joseph Sardano said the results reflect progress in building a broader, more diversified customer base. He noted that dedicated reimbursement codes took effect on January 1, 2026 and said physician conversations are increasingly focused on how to bring the company's superficial radiation therapy, or SRT, into their practices.

Results for the Quarter

Revenues were USD 6.0 million, a decrease of USD 0.9 million, or 13.0%, from USD 6.9 million. The company attributed the difference primarily to product mix, with more lower-priced SRT-100 systems than SRT-100 Vision systems, and to the absence of sales to its historically largest customer during the quarter.

Cost of sales was USD 2.7 million, against USD 4.2 million, a decrease of 35.7%. Gross Profit was USD 3.3 million, against USD 2.7 million, an increase of 22.2%, and gross margin was 55%, against 39.1%, which management attributed primarily to the mix of systems shipped, including a greater proportion of higher-margin SRT-100 units.

General and administrative expense was USD 2.3 million, against USD 1.9 million, an increase of 21.1%, primarily reflecting higher legal and professional fees, partly offset by lower insurance costs. Research and Development expense was USD 1.1 million, against USD 1.8 million, a decrease of 38.9%, which management linked to reduced lobbying costs and lower headcount.

Net Loss, Cash and Inventory

Net loss was USD 1.5 million, or USD 0.09 per share, against USD 0.9 million, or USD 0.06. Management noted that the prior-year quarter included an income tax benefit of approximately USD 1.5 million. Adjusted EBITDA, a non-GAAP measure, was negative USD 1.5 million, against negative USD 2.4 million.

Cash, restricted cash and cash equivalents were USD 12.9 million at September 30, 2026, against USD 15.2 million at June 30, 2026. Prepaid inventory was zero, against USD 0.6 million, and inventories were USD 18.0 million, against USD 18.5 million. The company had no outstanding borrowings under its revolving line of Credit at quarter end.

Shipments, Customers and Markets

The company shipped 26 systems, including eight carried over from the second quarter of 2026 because of financing approval timing, against 16 in the prior-year period. Excluding those eight, it shipped 18 systems, against six shipments to customers other than its historically largest customer a year earlier.

Management said it secured initial system purchases from two large private equity-backed dermatology groups and that customers can buy systems outright, use financing, rent or join its Fair Deal Agreement program. It said it is developing Sensus Link and other software and service offerings to add utilization-based recurring revenue.

In September, the company launched TreatSkinCancer.com, a consumer education resource, which management said drew nearly 1,000 visits during the initial launch period. It also advanced market development in Asia-Pacific, including Australia, New Zealand, China and Hong Kong, and plans to attend conferences in Europe and Korea in the fourth quarter. After quarter end, it placed its 1,000th SRT system.